AptaBio Therapeutics Inc. announced a private placement of series 1 unregistered non-guaranteed privately placed convertible bonds for a gross proceeds of KRW 38,900,000,000, and 1,037,574 registered convertible preferred shares at a price of KRW 10,698 per preferred share for gross proceeds of KRW 11,099,966,652; for aggregate gross proceeds of KRW 49,999,966,652 on August 16, 2023. The company is raising funding through third-party allotment rights issue for the preferred shares. The transaction has been approved by the board of directors of the company.